NEW YORK (GenomeWeb) – PerkinElmer reported after the close of the market on Thursday that is third quarter revenues were up 3 percent, or 10 percent on a constant-currency basis, compared to the same period a year ago.

For the three months ended Oct. 4, PerkinElmer posted Q3 revenues of $563.4 million, up from $542.0 million for Q3 a year ago and beating analysts' consensus estimate of $554.9 million. The company reported organic revenue growth of 6 percent year over year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.